Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Osteoporosis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Osteoporosis
    Once-Yearly Zoledronic Acid Approved in EU for Glucocorticoid-Induced Osteoporosis - (DGNews)
    TopAbstracts in Osteoporosis 06/23/2009 - (DGNews)
    Study Defines Strategy to Protect Bones in Women, Girls With Primary Ovarian Insufficiency - (DGNews)
    Zoledronic Acid Increases Bone Mineral Density in Men After Recent Hip Fracture: Presented at ENDO 09 - (DGDispatch)
    Treatment With Zoledronic Acid Shows Early, Persistent Reduction in the Risk of Fracture in Women: Presented at ENDO 09 - (DGDispatch)

    News archive

     Recent webcasts/CME - Osteoporosis
    The Evaluation and Management of Osteoporosis Encountered in Children and Adults with Developmental Disabilities

    Webcasts/CME archive

     Recent cases - Osteoporosis
      A Productive Cough
      Operative Management of a Subtrochanteric Fracture in Severe Osteoporosis: A Case Report
      Bilateral Femoral Neck Fractures Due to Transient Osteoporosis of Pregnancy: A Case Report
      A Clay-Shoveler's Fracture with Renal Transplantation and Osteoporosis: A Case Report
      Stress Fracture of the Femoral Neck in a 24-Year-Old Female with Anorexia Nervosa Induced Osteoporosis

      Cases archive
        




      my personal edition > osteoporosis > news
      divider

        E-Mail this DGNews to a colleague

      DGNews


      Endocrine Therapy Plus Zoledronic Acid Improves BMD in Premenopausal Women With Early Breast Cancer

        NEW YORK -- August 19, 2008 -- Concomitant zoledronic acid prevents bone loss in women with breast cancer during treatment with adjuvant endocrine therapy and improves bone mineral density (BMD) after treatment, according to a study published online and in the September edition of The Lancet Oncology.

        Michael Gnant, Professor, Medical University of Vienna, General Hospital of Vienna, Vienna, Austria, and colleagues conducted a prospective BMD substudy of patients included in the Austrian Breast and Colorectal Cancer Study Group trial-12 (ABCSG-12) to quantify the long-term effect of endocrine therapy and that of concomitant zoledronic acid on BMD.

        Premenopausal women with early-stage breast cancer (N = 404) participated in the substudy and were randomly assigned to receive 3-year treatment of either goserelin plus tamoxifen with or without zoledronic acid or goserelin plus anastrozole with or without zoledronic acid. Of these participants, 199 received endocrine therapy alone and 205 received endocrine therapy with zoledronic acid. Lumbar-spine and trochanter (hip) BMD was measured by dual-energy x-ray absorptiometry at baseline and at 6, 12, 36, and 60 months. The primary endpoint was change in BMD at 12 months.

        After 3 years of treatment, patients assigned endocrine therapy alone had significant loss of BMD at the lumbar spine and hip compared with baseline levels. At 5 years (2 years after completion of therapy), partial recovery of BMD was noted, although values were still below baseline. By contrast, in patients randomised to endocrine therapy and concomitant zoledronic acid, BMD remained stable at 3 years at the lumbar spine and hip and increased at 5 years above baseline values.

        This substudy shows that the addition of zoledronic acid to routine endocrine therapy in premenopausal women with early-stage breast cancer can sustain BMD during 3 years of endocrine therapy and actually improve it 2 years after completion of therapy.

        Prof. Gnant says, "The findings presented here offer important information related to bone health for premenopausal women undergoing adjuvant endocrine therapy."


        SOURCE: The Lancet Oncology




      E-Mail this DGNews to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send